A Double-Blind, Randomized, Controlled Trial for pUDK–HGF in the treatment of Critical Limb Ischemia induced diseases
Phase of Trial: Phase III
Latest Information Update: 06 Sep 2018
Price : $35 *
At a glance
- Drugs PUDK HGF (Primary)
- Indications Ischaemia
- Focus Therapeutic Use
- Sponsors Humanwell Healthcare
- 30 Aug 2018 Planned End Date changed from 1 Aug 2021 to 31 Dec 2020.
- 30 Aug 2018 Status changed from not yet recruiting to recruiting.
- 03 Aug 2018 New trial record